Rino Alvani Gani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rino Alvani Gani has a total of 544 co-authors. Here are the top co-authors by number of shared publications:
Irsan Hasan
Department of Gastroenterology & Hepatology, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta 10430, Indonesia
25 shared publications- Cosmas Rinaldi Adithya Lesmana
Hepatobiliary Division, Internal Medicine Department Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Indonesia
20 shared publications - Evy Yunihastuti
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
11 shared publications Laurentius A. Lesmana
Digestive Disease and Gastrointestinal Oncology Center, Medistra Hospital, Jakarta, Indonesia
8 shared publications- Laurentius Adrianto Lesmana
Department of Medicine, Medistra Hospital, Jakarta, Indonesia
8 shared publications Ali Sulaiman
Hepatology, Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
7 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Open Exploration Publishing in Exploration of digestive diseases
- Vol. 5, 1005139
The role of endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) in liver malignancy: case series and literature review
Percutaneous thermal ablation is widely used as a locoregional treatment for liver malignancies, but its feasibility and efficacy may be limited by unfavorable anatomy and access constraints. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has emerged as an alternative approach for selected tumor locations, particularly those located in the left lobe or caudate region. We report a two-center case series describing technical feasibility, safety, and short-term imaging outcomes of EUS-RFA in primary and secondary liver malignancies. We retrospectively reviewed five patients who underwent EUS-RFA for liver malignancy at two tertiary centers. Diagnoses included hepatocellular carcinoma (HCC; n = 2), intrahepatic cholangiocarcinoma (iCCA; n = 1), colorectal liver metastasis (CRLM; n = 1), and pancreatic neuroendocrine tumor (PNET) liver metastasis (n = 1). EUS-RFA was performed using linear echoendoscopes and a radiofrequency generator connected to an EUS-RFA needle with a 1-cm active tip. Outcomes included technical success, procedural safety, and radiologic response at follow-up. Technical success was achieved in all five patients (100%). No immediate major procedure-related complications (bleeding, perforation, infection) were observed. At follow-up imaging, both HCC patients demonstrated stable disease at 1 month. The iCCA and CRLM patients demonstrated stable disease at 4 months. The PNET liver metastasis progressed during the longer follow-up period (8 months). In this small retrospective case series, EUS-RFA was technically feasible in carefully selected patients with liver malignancies, and no immediate major procedure-related complications were observed. EUS-RFA may serve as a complementary technique when percutaneous access is technically challenging or not feasible. Larger prospective studies are needed to better define its role in the multidisciplinary management of liver malignancies.
- 22 October 2026
- Published by Open Exploration Publishing in Exploration of digestive diseases
- Vol. 5, 1005139
Open AccessThe role of endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) in liver malignancy: case series and literature review
Percutaneous thermal ablation is widely used as a locoregional treatment for liver malignancies, but its feasibility and efficacy may be limited by unfavorable anatomy and access constraints. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has emerged as an alternative approach for selected tumor locations, particularly those located in the left lobe or caudate region. We report a two-center case series describing technical feasibility, safety, and short-term imaging outcomes of EUS-RFA in primary and secondary liver malignancies. We retrospectively reviewed five patients who underwent EUS-RFA for liver malignancy at two tertiary centers. Diagnoses included hepatocellular carcinoma (HCC; n = 2), intrahepatic cholangiocarcinoma (iCCA; n = 1), colorectal liver metastasis (CRLM; n = 1), and pancreatic neuroendocrine tumor (PNET) liver metastasis (n = 1). EUS-RFA was performed using linear echoendoscopes and a radiofrequency generator connected to an EUS-RFA needle with a 1-cm active tip. Outcomes included technical success, procedural safety, and radiologic response at follow-up. Technical success was achieved in all five patients (100%). No immediate major procedure-related complications (bleeding, perforation, infection) were observed. At follow-up imaging, both HCC patients demonstrated stable disease at 1 month. The iCCA and CRLM patients demonstrated stable disease at 4 months. The PNET liver metastasis progressed during the longer follow-up period (8 months). In this small retrospective case series, EUS-RFA was technically feasible in carefully selected patients with liver malignancies, and no immediate major procedure-related complications were observed. EUS-RFA may serve as a complementary technique when percutaneous access is technically challenging or not feasible. Larger prospective studies are needed to better define its role in the multidisciplinary management of liver malignancies.
- Open Access
- 8 September 2026
- Published by MDPI AG in Preprints.org
Endoscopic Sleeve Gastroplasty in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients with Obesity Who Failed Dietary and Weight-Loss Programs: A Real-Life Case Series in Unselected Patients
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent, is closely linked to obesity, and carries significant hepatic and cardiometabolic risk. Current first-line lifestyle interventions often yield suboptimal results. Endoscopic sleeve gastroplasty (ESG), a minimally invasive endobariatric procedure, has shown safety and efficacy for weight loss, but evidence, particularly regarding liver-specific outcomes in Asian populations, is limited. We evaluated the effectiveness and safety of ESG on hepatic steatosis, liver function, and weight in unselected Asian patients with MASLD and obesity. Methods: This case series reports six patients with MASLD who underwent ESG for obesity management after failing dietary and weight-loss programs. Patients were followed at 3 and 6 months. Primary outcomes were changes in steatosis (ultrasound attenuation parameter, UAP), liver function (alanine aminotransferase, ALT), and procedure-related adverse events; secondary outcomes were total body weight loss (%TBWL), change in body mass index (ΔBMI), and technical success. Results: The cohort comprised three men and three women with a mean age of 47.8 ± 7.52 years and a median baseline body mass index of 32.37 (interquartile range 29.24–38.00) kg/m². All patients with available follow-up achieved normalization of UAP and ALT after the procedure, and no major complications occurred. A weight loss of −9.33 ± 6.80 kg with a %TBWL of −9.97 ± 5.29% was observed (p = 0.02), and all procedures were technically successful. Conclusions: ESG appears to be a promising treatment for hepatic steatosis in patients with obesity and MASLD, but these findings should be validated through larger, controlled studies.
- 8 September 2026
- Published by MDPI AG in Preprints.org
Open AccessEndoscopic Sleeve Gastroplasty in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients with Obesity Who Failed Dietary and Weight-Loss Programs: A Real-Life Case Series in Unselected Patients
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent, is closely linked to obesity, and carries significant hepatic and cardiometabolic risk. Current first-line lifestyle interventions often yield suboptimal results. Endoscopic sleeve gastroplasty (ESG), a minimally invasive endobariatric procedure, has shown safety and efficacy for weight loss, but evidence, particularly regarding liver-specific outcomes in Asian populations, is limited. We evaluated the effectiveness and safety of ESG on hepatic steatosis, liver function, and weight in unselected Asian patients with MASLD and obesity. Methods: This case series reports six patients with MASLD who underwent ESG for obesity management after failing dietary and weight-loss programs. Patients were followed at 3 and 6 months. Primary outcomes were changes in steatosis (ultrasound attenuation parameter, UAP), liver function (alanine aminotransferase, ALT), and procedure-related adverse events; secondary outcomes were total body weight loss (%TBWL), change in body mass index (ΔBMI), and technical success. Results: The cohort comprised three men and three women with a mean age of 47.8 ± 7.52 years and a median baseline body mass index of 32.37 (interquartile range 29.24–38.00) kg/m². All patients with available follow-up achieved normalization of UAP and ALT after the procedure, and no major complications occurred. A weight loss of −9.33 ± 6.80 kg with a %TBWL of −9.97 ± 5.29% was observed (p = 0.02), and all procedures were technically successful. Conclusions: ESG appears to be a promising treatment for hepatic steatosis in patients with obesity and MASLD, but these findings should be validated through larger, controlled studies.
- Open Access
- 1 September 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 95
Aligning policy and clinical guidelines for albumin use in cirrhosis: insights from Indonesia Hepatology Medical Workgroup Meeting
Background: Cirrhosis continues to be a major health burden in Indonesia, with high mortality and morbidity related to complications including ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS). Although international guidelines strongly recommend albumin therapy for these complications, in Indonesia the adoption of international guidelines has been limited by universal healthcare policy and albumin indications defined in the National Formulary. The Indonesia Hepatology Medical Workgroup Meeting (December 2025) was convened to address barriers to the implementation of the newly launched National Cirrhosis Guideline, outline potential solutions, and discuss emerging topics such as long-term albumin (LTA) therapy and recombinant albumin (RA). Methods: Seven hepatology experts from tertiary care centers completed a pre-meeting survey and participated in structured discussions on local barriers to implementation of the National Cirrhosis Guideline, evolution of treatment towards LTA, and clinical considerations for RA. Results: The workgroup welcomed the National Cirrhosis Guideline for defining clear albumin indications in large-volume paracentesis (LVP), SBP, and HRS that align with international standards and should serve as the primary clinical guidance for management of cirrhosis in Indonesia. Cost-effectiveness evidence supports albumin use for SBP, HRS, and LVP; however, the current real-world management is still suboptimal. The primary barriers to implementation of the National Cirrhosis Guideline were the restricted indications and criteria defined within the National Formulary. The discussion indicated that albumin underutilization, lack of standardized care, and limited adoption of LTA treatment were primarily due to unclear patient selection criteria and dosing guidance. RA was recognized as a novel alternative, but concerns about long-term safety, immunogenicity, and functional equivalence persist. Conclusions: The National Cirrhosis Guideline represents a critical advancement toward standardized cirrhosis management in Indonesia. Immediate priorities include National Formulary alignment, hospital protocol integration, and clinician education to support evidence-based albumin utilization nationwide. While LTA offers potential disease-modifying benefits, its routine adoption remains constrained by economic and policy considerations, and it should be considered selectively when clinically appropriate. While RA may offer scalability and consistency, long-term safety, immunogenicity, and non-oncotic functional equivalence require further confirmation before routine clinical adoption.
- 1 September 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 95
Open AccessAligning policy and clinical guidelines for albumin use in cirrhosis: insights from Indonesia Hepatology Medical Workgroup Meeting
Background: Cirrhosis continues to be a major health burden in Indonesia, with high mortality and morbidity related to complications including ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS). Although international guidelines strongly recommend albumin therapy for these complications, in Indonesia the adoption of international guidelines has been limited by universal healthcare policy and albumin indications defined in the National Formulary. The Indonesia Hepatology Medical Workgroup Meeting (December 2025) was convened to address barriers to the implementation of the newly launched National Cirrhosis Guideline, outline potential solutions, and discuss emerging topics such as long-term albumin (LTA) therapy and recombinant albumin (RA). Methods: Seven hepatology experts from tertiary care centers completed a pre-meeting survey and participated in structured discussions on local barriers to implementation of the National Cirrhosis Guideline, evolution of treatment towards LTA, and clinical considerations for RA. Results: The workgroup welcomed the National Cirrhosis Guideline for defining clear albumin indications in large-volume paracentesis (LVP), SBP, and HRS that align with international standards and should serve as the primary clinical guidance for management of cirrhosis in Indonesia. Cost-effectiveness evidence supports albumin use for SBP, HRS, and LVP; however, the current real-world management is still suboptimal. The primary barriers to implementation of the National Cirrhosis Guideline were the restricted indications and criteria defined within the National Formulary. The discussion indicated that albumin underutilization, lack of standardized care, and limited adoption of LTA treatment were primarily due to unclear patient selection criteria and dosing guidance. RA was recognized as a novel alternative, but concerns about long-term safety, immunogenicity, and functional equivalence persist. Conclusions: The National Cirrhosis Guideline represents a critical advancement toward standardized cirrhosis management in Indonesia. Immediate priorities include National Formulary alignment, hospital protocol integration, and clinician education to support evidence-based albumin utilization nationwide. While LTA offers potential disease-modifying benefits, its routine adoption remains constrained by economic and policy considerations, and it should be considered selectively when clinically appropriate. While RA may offer scalability and consistency, long-term safety, immunogenicity, and non-oncotic functional equivalence require further confirmation before routine clinical adoption.
- Open Access
- 7 July 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial
Background and Aim: No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high‐risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomnia, but evidence in cirrhosis is limited. Methods: Restoring Sleep in End‐Stage Liver Disease (RESTORE) is a prospective, double‐blind, placebo‐controlled, crossover trial of Lemborexant for patients with cirrhosis in Cipto Mangunkusumo National Referral Hospital. We randomized 82 patients into three arms: Placebo ( n = 28), 5 mg Lemborexant ( n = 28), and 10 mg Lemborexant ( n = 26). Efficacy was assessed via Pittsburgh Sleep Quality Index (PSQI) over a 2‐week period. Safety was evaluated using the EncephalApp Stroop Test for hepatic encephalopathy and liver function tests including AST, ALT, and total bilirubin. PSQI was reevaluated post‐crossover at week 4 to investigate rebound insomnia. Results: Lemborexant significantly reduced PSQI at week 2 in both 5 mg (MD: −7.0 ± 3.15; p < 0.001) and 10 mg groups (MD: −8.27 ± 2.68; p < 0.001), indicating better sleep quality. The 5 mg group showed improved Stroop Test reaction time (MD: −23.5 ± 31.3; p < 0.001), suggesting better cognitive function, whereas 10 mg showed a mild but significant increase in reaction time (MD: 16.7 ± 41.3; p = 0.048). Liver function was not different across treatment groups. Post‐crossover analysis showed persistent low PSQI scores in active groups who were switched to placebo. Patients who initially received placebo demonstrated improved sleep after receiving Lemborexant. Conclusion: Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow‐up are warranted to strengthen evidence. ClinicalTrials.gov: NCT07480096.
- 7 July 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessClinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial
Background and Aim: No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high‐risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomnia, but evidence in cirrhosis is limited. Methods: Restoring Sleep in End‐Stage Liver Disease (RESTORE) is a prospective, double‐blind, placebo‐controlled, crossover trial of Lemborexant for patients with cirrhosis in Cipto Mangunkusumo National Referral Hospital. We randomized 82 patients into three arms: Placebo ( n = 28), 5 mg Lemborexant ( n = 28), and 10 mg Lemborexant ( n = 26). Efficacy was assessed via Pittsburgh Sleep Quality Index (PSQI) over a 2‐week period. Safety was evaluated using the EncephalApp Stroop Test for hepatic encephalopathy and liver function tests including AST, ALT, and total bilirubin. PSQI was reevaluated post‐crossover at week 4 to investigate rebound insomnia. Results: Lemborexant significantly reduced PSQI at week 2 in both 5 mg (MD: −7.0 ± 3.15; p < 0.001) and 10 mg groups (MD: −8.27 ± 2.68; p < 0.001), indicating better sleep quality. The 5 mg group showed improved Stroop Test reaction time (MD: −23.5 ± 31.3; p < 0.001), suggesting better cognitive function, whereas 10 mg showed a mild but significant increase in reaction time (MD: 16.7 ± 41.3; p = 0.048). Liver function was not different across treatment groups. Post‐crossover analysis showed persistent low PSQI scores in active groups who were switched to placebo. Patients who initially received placebo demonstrated improved sleep after receiving Lemborexant. Conclusion: Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow‐up are warranted to strengthen evidence. ClinicalTrials.gov: NCT07480096.
- 2 November 2025
- Published by The Running Line in Advancements in Life Sciences
- Vol. 12 (3) , 623
Prevalence and Risk of Hepatitis Infection in Infants Associated with Maternal Health History: A Cross-Sectional Study in Indonesia
Ackground: Hepatitis is a significant public health concern in Indonesia, with the government prioritizing the prevention of mother-to-child transmission of hepatitis B. This study aimed to evaluate the influence of antenatal care (ANC), pregnancy and parturition conditions, hepatitis B immunizations, and healthcare accessibility on the incidence of hepatitis among infants.Methods: A cross-sectional analysis was conducted using data from the 2018 Basic Health Survey (Riskesdas) in Indonesia, examining 10,293 infants aged 6–12 months. Multivariate logistic regression was performed on a final sample of 7,434 cases with complete data. The sampling method used in this research is multistage cluster sampling, which is a common approach for large, nationally representative surveys such as Riskesdas.Results: Hepatitis was identified in 0.5% of infants. Significant associations were found between hepatitis incidence and maternal pregnancy disorders (aPOR = 1.92, 95% CI = 1.03–3.6) and abnormal parturition methods (aPOR = 2.19, 95% CI = 1.14–4.18). However, ANC history and hepatitis B immunization did not show significant associations.Conclusion: Comprehensive and timely ANC to address pregnancy disorders and ensure normal parturition can significantly reduce hepatitis risk in infants. Public health interventions should focus on maternal health education and healthcare access, particularly in rural areas.Keywords: Antenatal Care, Hepatitis Infection, Infant, Parturition, Pregnancy
- 2 November 2025
- Published by The Running Line in Advancements in Life Sciences
- Vol. 12 (3) , 623
Prevalence and Risk of Hepatitis Infection in Infants Associated with Maternal Health History: A Cross-Sectional Study in Indonesia
Ackground: Hepatitis is a significant public health concern in Indonesia, with the government prioritizing the prevention of mother-to-child transmission of hepatitis B. This study aimed to evaluate the influence of antenatal care (ANC), pregnancy and parturition conditions, hepatitis B immunizations, and healthcare accessibility on the incidence of hepatitis among infants.Methods: A cross-sectional analysis was conducted using data from the 2018 Basic Health Survey (Riskesdas) in Indonesia, examining 10,293 infants aged 6–12 months. Multivariate logistic regression was performed on a final sample of 7,434 cases with complete data. The sampling method used in this research is multistage cluster sampling, which is a common approach for large, nationally representative surveys such as Riskesdas.Results: Hepatitis was identified in 0.5% of infants. Significant associations were found between hepatitis incidence and maternal pregnancy disorders (aPOR = 1.92, 95% CI = 1.03–3.6) and abnormal parturition methods (aPOR = 2.19, 95% CI = 1.14–4.18). However, ANC history and hepatitis B immunization did not show significant associations.Conclusion: Comprehensive and timely ANC to address pregnancy disorders and ensure normal parturition can significantly reduce hepatitis risk in infants. Public health interventions should focus on maternal health education and healthcare access, particularly in rural areas.Keywords: Antenatal Care, Hepatitis Infection, Infant, Parturition, Pregnancy
- 25 October 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (1) , 149-162
Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure
Background Acute-on-chronic liver failure (ACLF) is a rapidly progressive syndrome marked by high short-term mortality. While diabetes mellitus (DM) is known to worsen liver-related outcomes, its specific impact on alcohol-related ACLF (ALD-ACLF) remains underexplored. This study aimed to assess the prognostic impact of DM on 90-day outcomes in ALD-ACLF using data from the APASL ACLF Research Consortium (AARC) database. Methods This observational study involved data from 5612 ACLF patients with documented 90-day outcomes. We identified 2096 patients with ALD-ACLF precipitated by alcoholic hepatitis. Patients with non-ALD etiologies, mixed etiologies, or non-alcoholic precipitants were excluded. Diabetic and non-diabetic patients were compared using 1:2 propensity score matching based on key baseline covariates. Survival outcomes were assessed using Kaplan–Meier analysis and multivariable Cox regression. Results After matching, 109 diabetic patients were compared with 218 well-matched non-diabetic controls. Diabetic patients had significantly lower overall survival (32 vs. 57%) and transplant-free survival (31 vs. 50%) compared to non-diabetics (log-rank p < 0.001). On multivariable Cox regression, DM was independently associated with increased 90-day mortality (HR 1.739, 95% CI 1.262–2.395, p < 0.001), along with elevated serum lactate (HR 1.187 per mmol/L, p < 0.001) and creatinine (HR 1.267 per mg/dL, p < 0.001). Conclusion Diabetes mellitus is a significant independent predictor of mortality in patients with ALD-ACLF. These findings highlight the need for early identification and integrated management of diabetes in ACLF care pathways to improve clinical outcomes.
- 25 October 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (1) , 149-162
Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure
Background Acute-on-chronic liver failure (ACLF) is a rapidly progressive syndrome marked by high short-term mortality. While diabetes mellitus (DM) is known to worsen liver-related outcomes, its specific impact on alcohol-related ACLF (ALD-ACLF) remains underexplored. This study aimed to assess the prognostic impact of DM on 90-day outcomes in ALD-ACLF using data from the APASL ACLF Research Consortium (AARC) database. Methods This observational study involved data from 5612 ACLF patients with documented 90-day outcomes. We identified 2096 patients with ALD-ACLF precipitated by alcoholic hepatitis. Patients with non-ALD etiologies, mixed etiologies, or non-alcoholic precipitants were excluded. Diabetic and non-diabetic patients were compared using 1:2 propensity score matching based on key baseline covariates. Survival outcomes were assessed using Kaplan–Meier analysis and multivariable Cox regression. Results After matching, 109 diabetic patients were compared with 218 well-matched non-diabetic controls. Diabetic patients had significantly lower overall survival (32 vs. 57%) and transplant-free survival (31 vs. 50%) compared to non-diabetics (log-rank p < 0.001). On multivariable Cox regression, DM was independently associated with increased 90-day mortality (HR 1.739, 95% CI 1.262–2.395, p < 0.001), along with elevated serum lactate (HR 1.187 per mmol/L, p < 0.001) and creatinine (HR 1.267 per mg/dL, p < 0.001). Conclusion Diabetes mellitus is a significant independent predictor of mortality in patients with ALD-ACLF. These findings highlight the need for early identification and integrated management of diabetes in ACLF care pathways to improve clinical outcomes.
- Open Access
- 28 May 2025
- Published by Open Exploration Publishing in Exploration of digestive diseases
- Vol. 4, 100576
The role of endoscopic ultrasound in esophageal and gastric varices management: a systematic review
Background: Esophageal varices (EV) and gastric varices (GV) are the most common portal hypertension complications in liver cirrhosis patients. Esophagogastroduodenoscopy (EGD) is the main standard procedure for variceal screening and treatment. Nonetheless, luminal evaluation sometimes cannot accurately evaluate the size of varices. Recently, endoscopic ultrasound (EUS) has been studied for EV and GV evaluation. Methods: Literature search was performed from PubMed, Scopus, and Cochrane Library databases until December 2022. Two independent reviewers (C.R.A.L. and T.P.) independently obtained and evaluated the selected studies according to pre-determined eligibility criteria. Results: Ten studies (four observational studies, three randomized controlled trials, and three retrospective reviews of case series) describing 593 patients met our eligibility criteria. Eight out of ten studies evaluated utilization of EUS for coil embolization and/or cyanoacrylate injection. All studies demonstrated excellent technical success rate of the procedure with good therapeutic efficacy, in terms of lowering the risk of recurrent bleeding. Significantly better findings were observed from groups treated with combination of coil and cyanoacrylate glue injection in comparison to monotherapy. One study also highlighted the higher possibility of developing pulmonary embolism in groups treated with conventional cyanoacrylate injection. Discussion: EUS-guided combination therapy appears to be a safe and effective modality for treating patients with gastric variceal bleeding with high number of complete obliteration and low risk of gastric variceal rebleeding. Further meta-analysis large-scale randomized clinical trials are still required to confirm these findings.
- 28 May 2025
- Published by Open Exploration Publishing in Exploration of digestive diseases
- Vol. 4, 100576
Open AccessThe role of endoscopic ultrasound in esophageal and gastric varices management: a systematic review
Background: Esophageal varices (EV) and gastric varices (GV) are the most common portal hypertension complications in liver cirrhosis patients. Esophagogastroduodenoscopy (EGD) is the main standard procedure for variceal screening and treatment. Nonetheless, luminal evaluation sometimes cannot accurately evaluate the size of varices. Recently, endoscopic ultrasound (EUS) has been studied for EV and GV evaluation. Methods: Literature search was performed from PubMed, Scopus, and Cochrane Library databases until December 2022. Two independent reviewers (C.R.A.L. and T.P.) independently obtained and evaluated the selected studies according to pre-determined eligibility criteria. Results: Ten studies (four observational studies, three randomized controlled trials, and three retrospective reviews of case series) describing 593 patients met our eligibility criteria. Eight out of ten studies evaluated utilization of EUS for coil embolization and/or cyanoacrylate injection. All studies demonstrated excellent technical success rate of the procedure with good therapeutic efficacy, in terms of lowering the risk of recurrent bleeding. Significantly better findings were observed from groups treated with combination of coil and cyanoacrylate glue injection in comparison to monotherapy. One study also highlighted the higher possibility of developing pulmonary embolism in groups treated with conventional cyanoacrylate injection. Discussion: EUS-guided combination therapy appears to be a safe and effective modality for treating patients with gastric variceal bleeding with high number of complete obliteration and low risk of gastric variceal rebleeding. Further meta-analysis large-scale randomized clinical trials are still required to confirm these findings.
- 1 April 2025
- Vol. 57 (2) , 200-211
Diagnostic Performance of INA-FRAIL and Study of Osteoporotic Fractures (SOF) Index Compared to Cardiovascular Health Study (CHS) in Diagnosing Frailty Syndrome in Older Adults with Heart Failure.
There is currently no gold standard for assessing frailty syndrome in older adults with heart failure. The Cardiovascular Health Study (CHS) is a reference standard for evaluating frailty in older adults with heart failure. Still, it requires a dynamometer and a spacious space, rendering it impractical in daily practice. The INA-FRAIL and Study of Osteoporotic Fractures (SOF) Index can often be easy to use; however, it has not been evaluated for diagnostic performance on older adults with heart failure in Indonesia. This study aimed to assess the diagnostic performance of INA-FRAIL and SOF-Index in diagnosing frailty in older adults with heart failure. This cross-sectional study evaluated the diagnostic performances of INA-FRAIL and SOF-Index compared to CHS as the gold standard in this study. The population was heart failure patients aged > 60 at Cipto Mangunkusumo Hospital. Analysis from 81 samples shows the prevalence of frailty based on CHS (35.5%), INA-FRAIL (23.5%), and SOF-Index (8,6%). Diagnostic performance analysis of INA-FRAIL showed a sensitivity of 55,17% (95% CI 35.69-73.55), specificity 94.23% (95% CI 84.05- 98.79), and AUC 0.805 (95% CI 0.698-0.912). Diagnostic performance analysis of SOF showed 20,69% sensitivity (95% CI 7.99 - 39.72), 98.08% specificity (95% CI 89.74 - 99.95), and AUC 0.719 (95% CI 0.595 - 0.843). INA-FRAIL and SOF-Index had a significant association with CHS. The cut-off point of INA-FRAIL ≥1 showed the highest sensitivity, while INA-FRAIL ≥2 showed the highest Youden index. The cut-off point of SOF ≥1 showed the highest sensitivity and the highest Youden index.
- 1 April 2025
- Vol. 57 (2) , 200-211
Diagnostic Performance of INA-FRAIL and Study of Osteoporotic Fractures (SOF) Index Compared to Cardiovascular Health Study (CHS) in Diagnosing Frailty Syndrome in Older Adults with Heart Failure.
There is currently no gold standard for assessing frailty syndrome in older adults with heart failure. The Cardiovascular Health Study (CHS) is a reference standard for evaluating frailty in older adults with heart failure. Still, it requires a dynamometer and a spacious space, rendering it impractical in daily practice. The INA-FRAIL and Study of Osteoporotic Fractures (SOF) Index can often be easy to use; however, it has not been evaluated for diagnostic performance on older adults with heart failure in Indonesia. This study aimed to assess the diagnostic performance of INA-FRAIL and SOF-Index in diagnosing frailty in older adults with heart failure. This cross-sectional study evaluated the diagnostic performances of INA-FRAIL and SOF-Index compared to CHS as the gold standard in this study. The population was heart failure patients aged > 60 at Cipto Mangunkusumo Hospital. Analysis from 81 samples shows the prevalence of frailty based on CHS (35.5%), INA-FRAIL (23.5%), and SOF-Index (8,6%). Diagnostic performance analysis of INA-FRAIL showed a sensitivity of 55,17% (95% CI 35.69-73.55), specificity 94.23% (95% CI 84.05- 98.79), and AUC 0.805 (95% CI 0.698-0.912). Diagnostic performance analysis of SOF showed 20,69% sensitivity (95% CI 7.99 - 39.72), 98.08% specificity (95% CI 89.74 - 99.95), and AUC 0.719 (95% CI 0.595 - 0.843). INA-FRAIL and SOF-Index had a significant association with CHS. The cut-off point of INA-FRAIL ≥1 showed the highest sensitivity, while INA-FRAIL ≥2 showed the highest Youden index. The cut-off point of SOF ≥1 showed the highest sensitivity and the highest Youden index.
- Open Access
- 15 November 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (6) , 1684-1711
Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH.
- 15 November 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (6) , 1684-1711
Open AccessNon-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH.
- 17 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 816-826
Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease–Related Acute-on-Chronic Liver Failure
INTRODUCTION: The prevalence of metabolic dysfunction–associated fatty liver disease (MAFLD) and its complication, MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF), is rising. Yet, factors determining patient outcomes in MAFLD-ACLF remain understudied. METHODS: Patients with MAFLD-ACLF were recruited from the Asian Pacific Association for the Study of the Liver-ACLF Research Consortium (AARC registry). The diagnosis of MAFLD-ACLF was made when the treating unit had identified the etiology of chronic liver disease as MAFLD (or previous nomenclature such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or non-alcoholic steatohepatitis-cirrhosis). Patients with coexisting other etiologies of chronic liver disease (such as alcohol, hepatitis B virus, hepatitis C virus, etc.) were excluded. Data were randomly split into derivation (n = 258) and validation (n = 111) cohorts at a 70:30 ratio. The primary outcome was 90-day mortality. Only the baseline clinical, laboratory features and severity scores were considered. RESULTS: The derivation group had 258 patients; 60% were male, with a mean age of 53. Diabetes was noted in 27% and hypertension in 29%. The dominant precipitants included viral hepatitis (hepatitis A virus and hepatitis E virus, 32%), drug-induced injury (drug-induced liver injury, 29%), and sepsis (23%). Model for End-Stage Liver Disease-Sodium (MELD-Na) and AARC scores on admission averaged 32 ± 6 and 10.4 ± 1.9. At 90 days, 51% survived. Nonviral precipitant, diabetes, bilirubin, international normalized ratio, and encephalopathy were independent factors influencing mortality. Adding diabetes and precipitant to MELD-Na and AARC scores, the novel MAFLD-MELD-Na score (+12 for diabetes, +12 for nonviral precipitant), and MAFLD-AARC score (+5 for each) were formed. These outperformed the standard scores in both cohorts. DISCUSSION: Almost half of patients with MAFLD-ACLF die within 90 days. Diabetes and nonviral precipitants such as drug-induced liver injury and sepsis lead to adverse outcomes. The new MAFLD-MELD-Na and MAFLD-AARC scores provide reliable 90-day mortality predictions for patients with MAFLD-ACLF.
- 17 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 816-826
Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease–Related Acute-on-Chronic Liver Failure
INTRODUCTION: The prevalence of metabolic dysfunction–associated fatty liver disease (MAFLD) and its complication, MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF), is rising. Yet, factors determining patient outcomes in MAFLD-ACLF remain understudied. METHODS: Patients with MAFLD-ACLF were recruited from the Asian Pacific Association for the Study of the Liver-ACLF Research Consortium (AARC registry). The diagnosis of MAFLD-ACLF was made when the treating unit had identified the etiology of chronic liver disease as MAFLD (or previous nomenclature such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or non-alcoholic steatohepatitis-cirrhosis). Patients with coexisting other etiologies of chronic liver disease (such as alcohol, hepatitis B virus, hepatitis C virus, etc.) were excluded. Data were randomly split into derivation (n = 258) and validation (n = 111) cohorts at a 70:30 ratio. The primary outcome was 90-day mortality. Only the baseline clinical, laboratory features and severity scores were considered. RESULTS: The derivation group had 258 patients; 60% were male, with a mean age of 53. Diabetes was noted in 27% and hypertension in 29%. The dominant precipitants included viral hepatitis (hepatitis A virus and hepatitis E virus, 32%), drug-induced injury (drug-induced liver injury, 29%), and sepsis (23%). Model for End-Stage Liver Disease-Sodium (MELD-Na) and AARC scores on admission averaged 32 ± 6 and 10.4 ± 1.9. At 90 days, 51% survived. Nonviral precipitant, diabetes, bilirubin, international normalized ratio, and encephalopathy were independent factors influencing mortality. Adding diabetes and precipitant to MELD-Na and AARC scores, the novel MAFLD-MELD-Na score (+12 for diabetes, +12 for nonviral precipitant), and MAFLD-AARC score (+5 for each) were formed. These outperformed the standard scores in both cohorts. DISCUSSION: Almost half of patients with MAFLD-ACLF die within 90 days. Diabetes and nonviral precipitants such as drug-induced liver injury and sepsis lead to adverse outcomes. The new MAFLD-MELD-Na and MAFLD-AARC scores provide reliable 90-day mortality predictions for patients with MAFLD-ACLF.